tert-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate

Catalog No. :
ACKAXD605
CAS No. :
2380273-93-6
Molecular Formula :
C28H40N4O10
Molecular Weight :
592.65

IUPAC Name:tert-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate

tert-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate
IUPAC Nametert-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate
Molecular FormulaC28H40N4O10
Molecular Weight592.65
SMILESCC(C)(C)OC(=O)NCCOCCOCCOCCOCC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
InChI KeyKYKLFSPNEXVODS-UHFFFAOYSA-N
Synonymtert-Butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate
CAS No.2380273-93-6

Synthetic Route by SureRoute

1. ACKAXD605 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  4. Then
  5. ACKAXD605 route product structure diagram
    ACKAXD6052380273-93-6
Inquiry

2. ACKAXD605 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHSLF863 route compound structure diagram
    ACHSLF863876345-13-0 In Stock
  2. Plus
  3. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  4. Then
  5. ACKAXD605 route product structure diagram
    ACKAXD6052380273-93-6
Inquiry

Comments (0)